Skip to content
Open access

Myeloid-derived suppressor cells confer stemness to esophageal cancer cells through the HNF1A/CXCL1 signaling axis

Sep 2026 · Cancer Immunology and Immunotherapy · 0 citations

TL;DR

It is shown that MDSCs accelerate ESCC growth in both immunocompetent and T cell-deficient mice, indicating an intrinsic tumor-promoting program and targeting this pathway may complement T cell-focused therapies in ESCC.

Abstract

Our previous work established that myeloid-derived suppressor cells (MDSCs) were abundant in human esophageal squamous cell carcinoma (ESCC) and correlated with adverse prognosis. Yet their direct, T cell-independent impact on tumor propagation remains undefined. Here, we show that MDSCs accelerate ESCC growth in both immunocompetent and T cell-deficient mice, indicating an intrinsic tumor-promoting program. Anti-Gr1-mediated MDSC depletion or IL-1β neutralization reduced intratumoral HNF1A expression, blunted CXCL1 promoter activity and down-regulated the stemness transcription factors Oct4, Nanog and Sox9. Deletion of HNF1A in tumor cells abolished MDSC-driven expansion of cancer stem cells (CSCs) and abrogated tumor initiation, whereas exogenous IL-1β reinstated CSC frequencies. Thus, MDSC-derived IL-1β licenses an HNF1A–CXCL1 axis that sustains CSC properties independently of adaptive immunity. Targeting this pathway may complement T cell-focused therapies in ESCC. Graphical abstract Myeloid-derived suppressor cells license stem-like properties in esophageal squamous cell carcinoma via HNF1A-driven CXCL1 signaling and predict poor prognosis.

Read PDF

Similar papers

Open access Aug 2026

Myeloid-derived MIF is a central regulator of MDSC-driven T-cell dysfunction in head and neck squamous cell carcinoma

These findings identify myeloid-derived MIF as a central regulator of the MDSC–Treg–CD8⁺ axis in HNSCC and support myeloid-targeted MIF inhibition as a strategy to reprogram the TME and enhance responses to immune checkpoint blockade.

Suvekshya Shrestha, F. Lamenza, Natalie Kazmierowicz et al. · 0 citations
Review Open access Aug 2026

Myeloid-derived suppressor cells in laryngeal squamous cell carcinoma: an underexplored immunosuppressive axis and strategic target for overcoming checkpoint inhibitor resistance

It is argued that combining MDSC-targeting strategies with PD-1 blockade merits dedicated clinical investigation in this disease and supported MDSCs as a clinically tractable immunosuppressive node in LSCC.

Guan-Jiang Huang, Xue-Sen Yang, Peijie Li et al. · 1 citation
Review Open access Sep 2026

Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects

This review systematically summarizes the classification and identification of myeloid-derived suppressor cells, their biological properties in the context of tumors and autoimmune diseases, genetic and signaling pathway regulatory mechanisms, differentiation skewing in the TME, and cellular interactions with the TME.

Rong-Jun Deng, Xiu-Yun Bai, Jue Yang et al. · 0 citations
Open access Sep 2026

Targeting SHMT2 reverses lactate-driven CAF-mediated T-cell exclusion and sensitizes HNSCC to anti-PD-1 immunotherapy

It is suggested that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.

He-Lei Yan, Lu Wang, Zhen Li et al. · 0 citations
Open access Aug 2026

EphA4 Mediates Pro- and Antitumoral Effects Through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma.

Head and Neck Head and Neck Squamous Cell Carcinoma (HNSCC) is driven by an immunosuppressive tumor microenvironment (TME). We examined the immune-modulatory role of EphA4 in HNSCC using spatial analysis, multi-compartment RNA-sequencing from Oral Cavity Squamous Cell Carcinoma (OCSCC), and three genetically engineered...

S. Corbo, Khalid N. M. Abdelazeem, D. Nguyen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.